These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1530 related items for PubMed ID: 23764390

  • 1. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
    Croze ML, Soulage CO.
    Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
    [Abstract] [Full Text] [Related]

  • 2. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
    Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PG.
    Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
    Tang G, Li S, Zhang C, Chen H, Wang N, Feng Y.
    Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
    [Abstract] [Full Text] [Related]

  • 5. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
    Pustotina O, Myers SH, Unfer V, Rasulova I.
    Gynecol Obstet Invest; 2024 Sep; 89(2):131-139. PubMed ID: 38295772
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Insulin-induced activation of glycerol-3-phosphate acyltransferase by a chiro-inositol-containing insulin mediator is defective in adipocytes of insulin-resistant, type II diabetic, Goto-Kakizaki rats.
    Farese RV, Standaert ML, Yamada K, Huang LC, Zhang C, Cooper DR, Wang Z, Yang Y, Suzuki S, Toyota T.
    Proc Natl Acad Sci U S A; 1994 Nov 08; 91(23):11040-4. PubMed ID: 7972005
    [Abstract] [Full Text] [Related]

  • 8. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
    Højlund K.
    Dan Med J; 2014 Jul 08; 61(7):B4890. PubMed ID: 25123125
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
    Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela V.
    Gynecol Endocrinol; 2013 Apr 08; 29(4):375-9. PubMed ID: 23336594
    [Abstract] [Full Text] [Related]

  • 11. Inositol: history of an effective therapy for Polycystic Ovary Syndrome.
    Bizzarri M, Carlomagno G.
    Eur Rev Med Pharmacol Sci; 2014 Jul 08; 18(13):1896-903. PubMed ID: 25010620
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reflections on inositol(s) for PCOS therapy: steps toward success.
    Nestler JE, Unfer V.
    Gynecol Endocrinol; 2015 Jul 08; 31(7):501-5. PubMed ID: 26177098
    [Abstract] [Full Text] [Related]

  • 14. Soy β-conglycinin improves glucose uptake in skeletal muscle and ameliorates hepatic insulin resistance in Goto-Kakizaki rats.
    Tachibana N, Yamashita Y, Nagata M, Wanezaki S, Ashida H, Horio F, Kohno M.
    Nutr Res; 2014 Feb 08; 34(2):160-7. PubMed ID: 24461318
    [Abstract] [Full Text] [Related]

  • 15. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z, Zhong C.
    Prog Neurobiol; 2013 Sep 08; 108():21-43. PubMed ID: 23850509
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
    Nordio M, Proietti E.
    Eur Rev Med Pharmacol Sci; 2012 May 08; 16(5):575-81. PubMed ID: 22774396
    [Abstract] [Full Text] [Related]

  • 18. The diabetic rat kidney mediates inosituria and selective urinary partitioning of D-chiro-inositol.
    Chang HH, Choong B, Phillips AR, Loomes KM.
    Exp Biol Med (Maywood); 2015 Jan 08; 240(1):8-14. PubMed ID: 25060739
    [Abstract] [Full Text] [Related]

  • 19. The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment.
    Cabrera-Cruz H, Oróstica L, Plaza-Parrochia F, Torres-Pinto I, Romero C, Vega M.
    Am J Physiol Endocrinol Metab; 2020 Feb 01; 318(2):E237-E248. PubMed ID: 31874063
    [Abstract] [Full Text] [Related]

  • 20. Inositols: From Established Knowledge to Novel Approaches.
    Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, Laganà AS, Chan SY, Bevilacqua A, Pkhaladze L, Benvenga S, Stringaro A, Barbaro D, Appetecchia M, Aragona C, Bezerra Espinola MS, Cantelmi T, Cavalli P, Chiu TT, Copp AJ, D'Anna R, Dewailly D, Di Lorenzo C, Diamanti-Kandarakis E, Hernández Marín I, Hod M, Kamenov Z, Kandaraki E, Monastra G, Montanino Oliva M, Nestler JE, Nordio M, Ozay AC, Papalou O, Porcaro G, Prapas N, Roseff S, Vazquez-Levin M, Vucenik I, Wdowiak A.
    Int J Mol Sci; 2021 Sep 30; 22(19):. PubMed ID: 34638926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.